Literature DB >> 1601521

Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer.

D Vitolo1, T Zerbe, A Kanbour, C Dahl, R B Herberman, T L Whiteside.   

Abstract

Cytokine gene expression in tumor-infiltrating lymphocytes (TIL) in frozen-tissue sections of 2 types of human solid tumor--ovarian adenocarcinoma and invasive breast cancer--was examined by in situ hybridization with 35S-labeled cDNA probes for human cytokines. The proportion of cells containing mRNA able to hybridize to the antisense c-DNA probes for interleukin 2 (IL-2), tumor necrosis factor alpha (TNF alpha), interferon gamma (IFN gamma) or receptors for IL-2 (either p55 or p70) was also determined in human normal peripheral lymphoid tissues and inflammatory tissues. Few cells were positive for IL2 and TNF alpha mRNA in reactive human lymph nodes and tonsils. Inflammatory lesions, such as salpingitis or chronic active hepatitis, contained 10-20 times more cells positive for cytokine mRNA than reactive lymphoid tissue. In contrast, tumor-infiltrating lymphocytes (TIL) in the stroma of ovarian carcinomas or most ductal breast tumors only rarely expressed mRNA for TNF alpha, IL2 or IFN gamma. The intensity of mononuclear cell infiltration in these tumors correlated positively with the percentage of cells which expressed mRNA for IL-2, TNF alpha and IL-2R. In those ductal breast carcinomas which contained intracellular or intraductal mucins, up to 30% of lymphoid cells in the tumor stroma were positive for IL-2, TNF alpha, IFN gamma and IL-2R. Thus, strong evidence for local activation of mononuclear cells in situ, exemplified by the expression of genes for cytokines, was obtained only in inflammatory lesions and in mucin-producing breast carcinomas. In most carcinomas studied, few TIL expressed genes for cytokines as measured by in situ hybridization. Thus, human solid tumors appear to differ in their ability to induce gene expression for cytokines in TIL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601521     DOI: 10.1002/ijc.2910510412

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Cytokines and cytokine measurements in a clinical laboratory.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

Review 4.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 5.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

6.  Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer.

Authors:  Anjana Saha; Ashish Dhir; Anand Ranjan; Vibhuti Gupta; Narendra Bairwa; Ramesh Bamezai
Journal:  Immunogenetics       Date:  2005-03-09       Impact factor: 2.846

7.  High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.

Authors:  E Roussel; M C Gingras; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

8.  In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.

Authors:  B J Camp; S T Dyhrman; V A Memoli; L A Mott; R J Barth
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

9.  Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas.

Authors:  S Kudoh; Q Wang; O F Hidalgo; P Rayman; R R Tubbs; M G Edinger; V Kolenko; J Panuto; R Bukowski; J H Finke
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

10.  Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.

Authors:  D Risin; E S Kleinerman; Y Umezu; R P Pizzini; C M Balch; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.